Drug Profile


Latest Information Update: 18 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Northwestern University
  • Developer Northwestern University; Panther Biotechnology
  • Class Antineoplastics; Isoquinolines; Naphthalimides; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Haematological malignancies; Solid tumours

Most Recent Events

  • 01 Apr 2015 Numonafide licensed to Panther Biotechnology worldwide
  • 01 Apr 2015 Panther Biotechnology announces intention to submit IND to US FDA in 2015
  • 01 Apr 2015 Panther Biotechnology plans a phase I/II trial for Acute myeloid leukaemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top